Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Split virion, inactivated Influenza vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Age 16 to 60 years |
| Group 2 | EXPERIMENTAL | Age over 60 years |
| Name | Type | Description |
|---|---|---|
| Split virion, inactivated Influenza vaccine | BIOLOGICAL | 0.5 mL, Intramuscular (IM) |
Inclusion Criteria : * Aged 18 to 60 years or 61 years and older on the day of inclusion * Provision of a signed informed consent * Able to attend all scheduled visits and comply with all trial procedures * For a woman of child-bearing potential: avoid becoming pregnant (use of an effective method ...
Split virion, inactivated Influenza vaccine is used for influenza, specifically to prevent infection caused by the influenza virus. It is an inactivated vaccine that contains split virus particles, designed to elicit an immune response against the virus. The vaccine is being developed for use in adults, as studied in a clinical trial.
Split virion, inactivated Influenza vaccine is developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is responsible for the research and development of this vaccine candidate, which is currently in clinical trials for the prevention of influenza.
Split virion, inactivated Influenza vaccine is in Phase 2 of clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities. The vaccine is being studied for its immunogenicity and safety in adults, with one completed Phase 2 trial.
Split virion, inactivated Influenza vaccine has one completed clinical trial, identified as NCT00718146. This Phase 2 study evaluated the immunogenicity and safety of the inactivated, split-virion influenza vaccine, Northern Hemisphere 2008-2009 formulation, in 130 healthy adults aged 18 years and older in the United Kingdom.
Split virion, inactivated Influenza vaccine works by presenting inactivated, split virus particles to the immune system. This exposure triggers an immune response, including the production of antibodies, without causing the disease. The vaccine is designed to protect against influenza by priming the immune system to recognize and fight the virus upon future exposure.